Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Average Rating of “Buy” from Brokerages

Achieve Life Sciences, Inc. (NASDAQ:ACHV) has been assigned an average recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $14.6667.

Several analysts have weighed in on ACHV shares. Weiss Ratings raised shares of Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Canaccord Genuity Group set a $13.00 target price on shares of Achieve Life Sciences and gave the stock a “buy” rating in a research report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday, April 16th. Finally, Wall Street Zen upgraded Achieve Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th.

Achieve Life Sciences Stock Down 3.4%

NASDAQ:ACHV opened at $5.36 on Friday. The company has a market cap of $550.25 million, a PE ratio of -4.79 and a beta of 2.27. Achieve Life Sciences has a twelve month low of $2.00 and a twelve month high of $6.16. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.87. The company’s 50 day moving average is $4.74 and its two-hundred day moving average is $4.55.

Achieve Life Sciences (NASDAQ:ACHV) last released its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.11. Analysts anticipate that Achieve Life Sciences will post -0.91 EPS for the current year.

Institutional Investors Weigh In On Achieve Life Sciences

Large investors have recently bought and sold shares of the company. AQR Capital Management LLC purchased a new stake in Achieve Life Sciences in the first quarter valued at approximately $32,000. Magnolia Capital Advisors LLC purchased a new stake in Achieve Life Sciences in the fourth quarter valued at approximately $64,000. Jefferies Financial Group Inc. purchased a new stake in Achieve Life Sciences in the fourth quarter valued at approximately $84,000. HRT Financial LP purchased a new stake in Achieve Life Sciences in the fourth quarter valued at approximately $93,000. Finally, OneDigital Investment Advisors LLC purchased a new stake in Achieve Life Sciences in the third quarter valued at approximately $63,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.